早期非小细胞肺癌精准免疫疗法路线图

Immunotherapy has revolutionized the treatment of early-stage non-small cell lung cancer; yet many patients fail to achieve long-lasting benefit, partially because of incomplete or inconsistent biomarker predictions. Integrative multiomics, combining tumor-intrinsic, immune microenvironment, and systemic factors, offer a more comprehensive framework for precision immunotherapy, enabling improved patient stratification, treatment selection and outcomes.

免疫疗法为早期非小细胞肺癌的治疗带来了革命性的变化；然而，许多患者未能获得持久的治疗效果，部分原因是生物标志物预测不完整或不一致。综合多组学结合了肿瘤内在因素、免疫微环境因素和全身因素，为精准免疫疗法提供了一个更全面的框架，使患者分层、治疗选择和疗效得到改善。